simmitinib
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Oct 31, 2019 (NCT04058587)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
KDR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06656091 | Phase 3 | Oct 31, 2024 | Sun Yat-Sen University |
| NCT06577376 | Phase 1/Phase 2 (Phase 2) | Aug 26, 2024 | — |
| NCT06512428 | Phase 2 | Mar 15, 2024 | Harbin Medical University |
| NCT06132217 | Phase 1/Phase 2 (Phase 2) | Jan 30, 2024 | — |
| NCT04058587 | Phase 1 | Oct 31, 2019 | Shijiazhuang Pharma Group (CSPC) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harbin Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Shijiazhuang Pharma Group (CSPC) | For profit | 1 | 1 | 1 | 2019 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1